Compare BridgeBio Pharma Inc (BBIO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Williams Companies Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Williams Companies Inc trades at $72.66 (market cap $87.88B). The key difference: Williams Companies Inc is far larger — about 5.3× BridgeBio Pharma Inc's market cap, and Williams Companies Inc pays a 2.92% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WMB | |
|---|---|---|
Market Cap | $16.61B | $87.88B |
Sector | Health | Energy |
52-Week High | $90.17 | $79.40 |
52-Week Low | $47.29 | $56.51 |
Enterprise Value | $18.16B | $118.51B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
WMB trades at $70.4, down 1.9% on the day, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year EBITDA guidance to $8.4 billion. Strong profitability is evident with a 25.18% net income margin and 24.02% ROE, though valuation ratios like P/E of 28.05 appear elevated. The recent $5.5 billion acquisition of Momentum Midstream aims to bolster growth in the Haynesville region.
Outlook remains positive with analyst consensus strongly bullish (79% buy ratings) and a $87.14 price target, implying significant upside. Risks include execution of the Momentum integration, volatile energy prices, and high debt levels. Cash flow stability from fee-based contracts supports the dividend, but net cash flow turned negative in 2026 forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
